Microchip stock jumps nearly 10% after chipmaker lifts sales outlook on strong orders

Microchip stock jumps nearly 10% after chipmaker lifts sales outlook on strong orders

New York, January 6, 2026, 13:34 ET — Regular session

Microchip Technology (MCHP.O) shares climbed nearly 10% on Tuesday after the chipmaker lifted its fiscal third-quarter sales forecast, extending gains sparked by the update a day earlier. The stock was up 10.0% at $73.75 in early afternoon trading, after a 5.6% rise in after-hours trading on Monday. 1

The pre-announcement is an early check on demand for embedded chips used in everything from factory gear to cars, where investors have tracked an “inventory correction” — customers working down excess stock instead of placing new orders.

That matters because order momentum and factory utilization often drive profit swings in this part of the chip market. When plants run below capacity, under-utilization charges can squeeze margins, and excess inventory can trigger write-offs.

Microchip disclosed the update in an 8-K filing, furnishing a business update for the quarter ended Dec. 31, 2025. The filing attached the company’s release under Item 2.02, which covers results of operations and financial condition. 2

The Chandler, Arizona-based company said it now expects net sales of about $1.185 billion for its fiscal third quarter, above its prior outlook of $1.109 billion to $1.149 billion. Chief Executive Steve Sanghi said, “Our bookings activity was very strong in the December quarter,” and added, “We have seen a substantial reduction in our internal inventory.” 3

Microchip’s rally lifted other chipmakers tied to industrial and automotive demand. Texas Instruments rose 8.1% and NXP Semiconductors gained 7.7%, while Qualcomm and ON Semiconductor were up about 3.8% and 3.9%, respectively.

Brokerage commentary also turned more upbeat. Needham analyst N. Quinn Bolton kept a buy rating and raised his price target to $77, while Citi reaffirmed a buy rating with an $80 target, Barron’s reported. 4

But the company’s release flagged a long list of ways the rebound could stumble, including demand swings, customer order pushouts or cancellations, pricing pressure and changes in factory utilization. It also warned that managing inventory levels remains a key variable in quarterly results. 5

Investors now turn to Microchip’s Feb. 5 earnings report for details on margins and guidance for the March quarter, after Tuesday’s jump repriced near-term expectations. 6

Stock Market Today

Mastercard stock price: MA slips as Dow hits 50,000; jobs and CPI data next week

7 February 2026
New York, Feb 7, 2026, 11:18 EST — Market closed. Mastercard Incorporated shares (MA.N) last traded down 0.6% at $548.74 on Friday, after moving between $539.90 and $556.65. The stock is about 4% below its 52-week high, according to market data. That small drop still matters because payments names like Mastercard often trade as a clean read on consumer and travel spending. Heading into the new week, the focus shifts back to U.S. growth and rate expectations, which can move the group even when company news is thin. Friday’s tape was not thin. The Dow surged 2.47% to end above
Costco stock price retakes $1,000 — what traders are watching before Monday

Costco stock price retakes $1,000 — what traders are watching before Monday

7 February 2026
Costco closed Friday up 1.2% at $1,001.16, regaining the $1,000 level as about 2.36 million shares changed hands. January net sales rose 9.3% to $21.33 billion, with comparable sales up 7.1% and online sales surging 34.4%. Wells Fargo raised its price target to $950, maintaining a neutral rating. The next earnings call is set for March 5.
Johnson & Johnson stock price: What to watch after talc-case law firm ouster and new AFib data

Johnson & Johnson stock price: What to watch after talc-case law firm ouster and new AFib data

7 February 2026
Johnson & Johnson shares rose 0.9% to $239.99 Friday after a New Jersey appeals court disqualified Beasley Allen from state talc cases, citing improper coordination with a former J&J attorney. The ruling affects about 3,600 state lawsuits, while a related federal motion is pending. J&J also reported early 12-month pilot data for its investigational AFib device at a cardiology meeting.
Guardant Health stock jumps 7% as Evercore downgrades — what investors watch next
Previous Story

Guardant Health stock jumps 7% as Evercore downgrades — what investors watch next

GOLD stock pops as gold price nears record after Gold.com seals Monex deal
Next Story

GOLD stock pops as gold price nears record after Gold.com seals Monex deal

Go toTop